{"id":24909,"date":"2014-03-24T12:05:54","date_gmt":"2014-03-24T12:05:54","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=24909"},"modified":"2014-10-06T13:44:44","modified_gmt":"2014-10-06T13:44:44","slug":"volume-15-number-12-marchapril-2014","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/24909","title":{"rendered":"March\/April 2014: Volume 15 Number 3\/4"},"content":{"rendered":"

\"CROIThis issue of HTB includes first reports from the 21st Conference on Retroviruses and Opportunistic Infections (CROI) that was held in Boston from 3-6 March. <\/strong><\/p>\n

As usual, there is so much to report from this key meeting with many studies having a strong connection to UK research.<\/p>\n

We lead with the interim analysis from the PARTNER study, starting to properly quantify the residual risk of transmission on ART plus the potential for future PrEP to come from slow-release injections, perhaps every three months.<\/p>\n

ARV reports include three phase-2 studies on pipeline compounds from different classes: doravirine, GSK-744 and BMS-068. Results from three large ARV strategy trials also provide datasets on choice of initial and maintenance therapy: PIVOT, NEAT001 and ACTG 5257, plus a report on whether the target dose for efavirenz could be set lower.<\/p>\n

Studies on PMTCT report on the high rate of maternal death during pregnancy in South Africa and a caution about low bone mineral density in infants exposed to tenofovir that are not infected.<\/p>\n

Paediatric news covers an exciting pipeline of new formulations and the safety of switching to efavirenz for babies initially treated with lopinavir\/r. Also from South Africa, a tempering of expectations from clinical practice from access to Xpert TB testing.<\/p>\n

Cure research included the headline news about a second baby who may be cured and a detailed review on the current evidence supporting the gene therapy to modify CD4 cells.<\/p>\n

We also include six basic science reviews including new results on the prognostic value of IL-6 and D-dimer, HIV persistence and cure research, management of immunologic non-responders and the value of the CD4:CD8 ratio – thanks to reports from Gareth Hardy and articles from Richard Jefferys best-on-the-net blog.<\/p>\n","protected":false},"excerpt":{"rendered":"

CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments…<\/p>\n","protected":false},"author":3,"featured_media":24924,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-24909","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=24909"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/24924"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=24909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=24909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=24909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}